NSE: WINDLAS · BSE: 543329 · ISIN INE0H5O01029
Windlas Biotech Limited stock analysis
Windlas Biotech Limited ranks #1297 in the TickerSutra evidence-ranked universe with a score of 54/100 and 95% data confidence. The latest captured fundamentals show ROCE of 15.9%, quarterly sales growth of 18.1% and quarterly profit growth of -0.1%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.06×
- Strong CFO/EBITDA of 1×
- 20.8% three-year sales CAGR
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- No calculated threshold risk in the current snapshot.
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹466cr | ₹53cr | ₹39cr | 11.0% |
| 2023 | ₹513cr | ₹60cr | ₹43cr | 12.0% |
| 2024 | ₹631cr | ₹78cr | ₹58cr | 12.0% |
| 2025 | ₹760cr | ₹94cr | ₹61cr | 12.0% |
| 2026 | ₹904cr | ₹105cr | ₹66cr | 12.0% |
| TTM | ₹942cr | ₹105cr | ₹66cr | 11.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
MANAGEMENT COMMENTARY
Signals from filed documents
So, what is the peak capacity utilization we can achieve? And coming to export growth, I think last 2 years, we have been doing very well, and we have been more focused in terms of rolling out BD team. So, do you see this kind of extraordinary growth of export continuing with our initiative?
Vansh, because we deal with a very large number of APIs and the -- whether there is a price gain impact and whether we benefit it or not, a lot of times, if we have stock, we offer it as a -- because we work in a transparent manner, we offer it at the same old price to our customers. And if there is a price increase, a sharp price increase in the market, our customers also accommodate that and give us that benefit ev
Excluding the impact of ESOP expenses, which are non-cash in nature, INR7.2 crores, our EBITDA grew 26% Y-o-Y to INR34 crores. PBT and PAT grew 27% and 37% Y-o-Y to INR30 crores and INR25 crores, respectively, reflecting our continued focus on improving operational leverage. If we take into account noncash ESOP expenditure, INR7.2 crores, the company reported EBITDA INR27 crores, PBT INR23 crores and PAT INR18 crores
And having said that, we would like to emphasize that we remain extremely positive in terms of the long-term growth potential that is available in our TGx and Institutional vertical, which continues to be supported by favourable macroeconomic factors, increasing demand for affordable health care and our internal AAA strategy. Windlas Biotech Limited August 11, 2026 Page 8 of 16 We continue to work on geographic expan
So, because we already finished all the supportive facilities work in terms of getting the area ready, in terms of laying out the water system extensions, in terms of getting the AHUs all installed. Of course, we are also looking at is it just a straight capacity expansion? Or can we look at some more variants in that.
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…